(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
To learn more and schedule a consultation, call us at 206-209-0988
Beyond potential fatigue, tirzepatide is associated with several well-documented side effects, predominantly affecting the gastrointestinal system
What to Expect Mini check-in: brief health review with a licensed clinician Quick injection: tiny intramuscular shot in the deltoid or glute Thats it: no downtime
$124.99 1 BOTTLE $124.99/ea 10% OFF 2 BOTTLES $112.49/ea 15% OFF 3 BOTTLES $106.24/ea Description FDA Disclosure & Intended Use Storage Instructions Reviews (0) RUO COA Description Description 5-Amino-1MQ Capsules 50mg | Metabolic Research Compound Frontier Peptide Labs 5-Amino-1MQ Capsules are supplied as a high-purity research compound manufactured exclusively for laboratory research and scientific investigation